目的研究中药升降散对脓毒症患者血清Th1/Th2失衡及相关调节因子T-bet、GATA-3的干预作用。方法将55例脓毒症患者随机分为常规组(27例)和升降散组(28例),另将健康志愿者9例设为对照组。常规组患者给予西医常规治疗,升降散组患者在西医...目的研究中药升降散对脓毒症患者血清Th1/Th2失衡及相关调节因子T-bet、GATA-3的干预作用。方法将55例脓毒症患者随机分为常规组(27例)和升降散组(28例),另将健康志愿者9例设为对照组。常规组患者给予西医常规治疗,升降散组患者在西医常规治疗的基础上加用升降散100 m L,每日2次口服或鼻饲,对照组患者予口服安慰剂;3组的疗程均为3 d。比较治疗前后3组患者中医证候评分、白细胞计数(WBC)、C反应蛋白(CRP)、降钙素原(PCT)、血清Th1/Th2及其相关转录因子T-bet、GATA-3的水平。结果常规组与升降散组比较,治疗后中医证候评分、WBC、Th1/Th2和T-bet的差异均有统计学意义(P<0.05或P<0.01),2组患者治疗后CRP、PCT和GATA3的差异无统计学意义(P>0.05);2组与对照组比较,除GATA3外,其他各项指标差异均有统计学意义(P<0.01)。结论升降散可以改善脓毒症患者中医临床征候和炎症反应指标,对血清Th1/Th2失衡及其相关调节因子T-bet、GATA-3的水平具有干预作用。展开更多
Currently, therapy for squamous cancer （SqC） is unsatisfactory. Staphylococcal enterotoxin B （SEB） has strong immune regulatory activity. This study tests the hypothesis that SEB enforces the effect of immunothera...Currently, therapy for squamous cancer （SqC） is unsatisfactory. Staphylococcal enterotoxin B （SEB） has strong immune regulatory activity. This study tests the hypothesis that SEB enforces the effect of immunotherapy on SqC growth in a mouse model. C3H/HeN mice and the SqC cell line squamous cell carcinoma VII were used to create an SqC mouse model. Immune cell assessment was performed by flow cytometry. Real-time RT-PCR and western blotting were used to evaluate target molecule expression. An apoptosis assay was used to assess the suppressive effect of T helper-9 （Th9） cells on the SqC cells. The results showed that immunotherapy consisting of SEB plus SqC antigen significantly inhibited SqC growth in the mice. The frequency of Th9 cells was markedly increased in the SqC tissue and mouse spleens after treatment. SEB markedly increased the levels of signal transducer and activator of transcription 5 phosphorylation and the expression of histone deacetylase-1 （HDAC1） and PU.1 （the transcription factor of the interleukin 9 （IL-9） gene） in CD4^＋ T cells. Exposure to SqC-specific Th9 cells markedly induced SqC cell apoptosis both in vitro and in vivo. In conclusion, the administration of SEB induces Th9 cells in SqC-bearing mice, and theseTh9 cells inhibit SqC growth.展开更多
文摘目的研究中药升降散对脓毒症患者血清Th1/Th2失衡及相关调节因子T-bet、GATA-3的干预作用。方法将55例脓毒症患者随机分为常规组(27例)和升降散组(28例),另将健康志愿者9例设为对照组。常规组患者给予西医常规治疗,升降散组患者在西医常规治疗的基础上加用升降散100 m L,每日2次口服或鼻饲,对照组患者予口服安慰剂;3组的疗程均为3 d。比较治疗前后3组患者中医证候评分、白细胞计数(WBC)、C反应蛋白(CRP)、降钙素原(PCT)、血清Th1/Th2及其相关转录因子T-bet、GATA-3的水平。结果常规组与升降散组比较,治疗后中医证候评分、WBC、Th1/Th2和T-bet的差异均有统计学意义(P<0.05或P<0.01),2组患者治疗后CRP、PCT和GATA3的差异无统计学意义(P>0.05);2组与对照组比较,除GATA3外,其他各项指标差异均有统计学意义(P<0.01)。结论升降散可以改善脓毒症患者中医临床征候和炎症反应指标,对血清Th1/Th2失衡及其相关调节因子T-bet、GATA-3的水平具有干预作用。
基金This study was supported by grants from the Innovation of Science and Technology Commission of Shenzhen Municipality （JCYJ20140418095735538, JCYJ20120613161724279 JCYJ20120613172559904+3 种基金 JCYJ20130329110735981 JCYJ20120613173233810） International Collaboration Project （GJHZ20130408174112021） and the National Nature Science Foundation and China （81373176）.
文摘Currently, therapy for squamous cancer （SqC） is unsatisfactory. Staphylococcal enterotoxin B （SEB） has strong immune regulatory activity. This study tests the hypothesis that SEB enforces the effect of immunotherapy on SqC growth in a mouse model. C3H/HeN mice and the SqC cell line squamous cell carcinoma VII were used to create an SqC mouse model. Immune cell assessment was performed by flow cytometry. Real-time RT-PCR and western blotting were used to evaluate target molecule expression. An apoptosis assay was used to assess the suppressive effect of T helper-9 （Th9） cells on the SqC cells. The results showed that immunotherapy consisting of SEB plus SqC antigen significantly inhibited SqC growth in the mice. The frequency of Th9 cells was markedly increased in the SqC tissue and mouse spleens after treatment. SEB markedly increased the levels of signal transducer and activator of transcription 5 phosphorylation and the expression of histone deacetylase-1 （HDAC1） and PU.1 （the transcription factor of the interleukin 9 （IL-9） gene） in CD4^＋ T cells. Exposure to SqC-specific Th9 cells markedly induced SqC cell apoptosis both in vitro and in vivo. In conclusion, the administration of SEB induces Th9 cells in SqC-bearing mice, and theseTh9 cells inhibit SqC growth.
